A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

J. S. Chen, C. Hsu, N. J. Chiang, C. S. Tsai, H. H. Tsou, S. F. Huang, L. Y. Bai, I. C. Chang, H. S. Shiah, C. L. Ho, C. J. Yen, K. D. Lee, C. F. Chiu, K. M. Rau, M. S. Yu, Y. Yang, R. K. Hsieh, J. Y. Chang, Y. S. Shan, Y. ChaoLi Tzong Chen, Yung Hsin Chin, Tsai Rong Chung, Wei Lan Yu, Mei Hua Lee, Ling Fang Lin, Pei Chyi Lin, Ya Ling Wu, Hui Ling Wang, Li Ju Lu, Shiang Yi Chen, Chih Chu Wu, Te Chih Wei

研究成果: 雜誌貢獻文章同行評審

108 引文 斯高帕斯(Scopus)

指紋

深入研究「A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer」主題。共同形成了獨特的指紋。

Medicine & Life Sciences